This trial is studying whether a combination of the standard chemotherapy regimen for breast cancer plus the experimental drug atezolizumab is more effective than the standard chemotherapy regimen plus a placebo.
1 Primary · 13 Secondary · Reporting Duration: From date of randomization through study follow-up, to the time the target number of events is obtained, up to 5 years
1550 Total Participants · 2 Treatment Groups
Primary Treatment: Atezolizumab · Has Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|Did not meet criteria||50.0%|